Canada markets close in 3 hours 38 minutes

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
29.20+0.17 (+0.59%)
As of 12:21PM EDT. Market open.

Kura Oncology, Inc.

3033 Science Park Road
Suite 220
San Diego, CA 92121
United States
858 500 8800
http://www.kuraoncology.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees71

Key Executives

NameTitlePayExercisedYear Born
Dr. Troy Edward WilsonChairman, CEO & Pres908.26kN/A1969
Dr. Marc GrassoCFO & Chief Bus. Officer630.86kN/A1973
Ms. Kathleen FordChief Operating Officer492.28kN/A1947
Mr. James E. Basta J.D., Esq.Chief Legal Officer, Chief Compliance Officer & Corp. Sec.168.94kN/A1966
Mr. Pete De SpainVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Corporate Governance

Kura Oncology, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.